View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
March 25, 2013

AstraZeneca wins Crestor patent case

AstraZeneca has won a legal battle in the US to protect the patents on its cholesterol-lowering blockbuster drug Crestor (rosuvastatin calcium).

By Nikitha Ladda

AstraZeneca

AstraZeneca has won a legal battle in the US to protect the patents on its cholesterol-lowering blockbuster drug Crestor (rosuvastatin calcium).

Generic company Actavis and its partner EGIS Pharmaceuticals have agreed not to appeal a decision by the US Court of Appeals for the Federal Circuit, and will pay AstraZeneca a 39% royalty on sales of the drug until July 8, 2016 when exclusivity expires.

Both Actavis and EGIS conceded that Crestor’s substance patent is valid and enforceable.

The settlement agreement permits Actavis to begin selling is generic version of Crestor and its rosuvastatin zinc product on May 2, 2016.

Crestor generated $6.25bn worth of sales in 2012, down from $6.6bn in 2011 after losing patent protection in certain regions.

All claims and counterclaims will be dismissed in a consent judgment entered by the United States District Court for the District of Delaware.

AstraZeneca said in a statement that it will file the settlement agreement with the United States Federal Trade Commission and United States Department of Justice.

Earlier this month, AstraZeneca lost a lawsuit in Australia seeking to defend its patents for Crestor, which were challenged by Canadian generic drug maker Apotex.

The Federal Court of Australia ruled that three patents protecting Crestor (rosuvastatin) were invalid, overturning a prior ruling delivered in May 2012 which upheld the validity of AZ’s intellectual property.


Image: AstraZeneca headquarters in Paddington, London. Photo: Courtesy of AstraZeneca.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology